Corticosteroids in perinatal medicine: how to improve outcomes without affecting the developing brain?
Antenatal glucocorticoid therapy remains one of the most striking successes in the perinatal management of complicated pregnancies that result in premature birth. The anti-inflammatory and maturative properties of fluorocorticoids are such that all women at risk of preterm delivery before 34weeks gestation should be treated. Betamethasone is preferred to dexamethasone and no more than two courses, 2weeks apart, should be given until the evidence from further controlled trials on repeated doses becomes available. In particular, the early use of postnatal dexamethasone should be avoided in preterm infants because of the deleterious effects on neurological development, including not only cerebral palsy but also cognitive function and psychiatric-related behavior. Treatment with other steroids should be restricted to the context of randomized controlled trials.
Baud
Olivier
O
NICU and Neonatal Medicine, INSERM U676, Robert Debré Children's Hospital, 48 Bd Sérurier, Paris, France. olivier.baud@rdb.aphp.fr
Sola
Augusto
A
D000818:Animals; D001623:Betamethasone / Q000494:pharmacology; D001921:Brain / Q000187:drug effects* / Q000254:growth & development*; D003907:Dexamethasone / Q000494:pharmacology; D005260:Female; D005938:Glucocorticoids / Q000494:pharmacology*; D006801:Humans; D009474:Neurons / Q000187:drug effects; D007752:Obstetric Labor, Premature / Q000188:drug therapy; D010500:Perinatology; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy; D047928:Premature Birth; D016032:Randomized Controlled Trials as Topic
D005938:Glucocorticoids; D003907:Dexamethasone; D001623:Betamethasone